Topic: clinical trial data
The 144 patients who received Ampion in the latest trial outperformed tthe control cohort in terms of the responder criteria,
SAGE-217 triggered near-immediate, fairly durable improvements in patients with major depressive disorder.
The effect of the neuromodulator on wrinkles lasted for six months, suggesting it poses a threat to Allergan’s blockbuster Botox franchise.
The latest data drop shows 94% of children with advanced solid or primary CNS tumors remain on the oral TRK inhibitor.
The vote of confidence in the drug follows an early look at phase 2 data on the intracellular redox-modulating agent.
The trials linked the drug to improvements on a depression scale, teeing Sage up to file for approval next year and sending its stock up 44%.
Data presented by the RNAi pioneer Alnylam suggest its patisiran has the edge over Ionis’ inotersen in terms of safety and efficacy.
The data show an uptick in the proportion of patients able to sit unassisted and talk, fueling AveXis’ hopes of challenging Biogen’s Spinraza.
The IL-23 antibody easily outperformed J&J’s Stelara and AbbVie’s own Humira, setting it up to go before regulators next year.
The study linked synthetic oral endocannabinoid-mimetic anabasum to a statistically significant drop on a skin disease scale.